Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

There is an urgent need for Alzheimer's disease (AD) biomarkers-especially in the context of clinical trials. Biomarkers for early diagnosis, disease progression, and prediction are most critical, and disease-modification therapy development may depend on the discovery and validation of such markers. AddNeuroMed is a cross European, public/private consortium developed for AD biomarker discovery. We report here the development and design of AddNeuroMed and the progress toward the development of plasma markers. Despite the obstacles to such markers, we have identified a range of markers including CFH and A2M, both of which have been independently replicated. The experience of AddNeuroMed leads us to three overall conclusions. First, collaboration is essential. Second, design is paramount and combining modalities, such as imaging and proteomics, may be informative. Third, animal models are valuable in biomarker research. Most importantly, we have learned that plasma markers are feasible.

Original publication

DOI

10.1111/j.1749-6632.2009.05064.x

Type

Journal article

Journal

Ann N Y Acad Sci

Publication Date

10/2009

Volume

1180

Pages

36 - 46

Keywords

Alzheimer Disease, Biomarkers, Cooperative Behavior, Disease Progression, Europe, Humans